Dr. Adam Brufsky and the panel discuss the practical implementation of PI3K-directed triplet therapy in patients with HR-positive/HER2-negative metastatic breast cancer, focusing on treatment selection, sequencing considerations, and toxicity management.
Dr. Adam Brufsky leads a discussion on the evolving role of triplet therapy in HR-positive/HER2-negative metastatic breast cancer, focusing on the clinical implications of the INAVO-120 study and how its findings may influence treatment selection.
Dr. Adam Brufsky leads a discussion on the evolving role of triplet therapy in HR-positive/HER2-negative metastatic breast cancer, focusing on the clinical implications of the INAVO-120 study and how its findings may influence treatment selection.
Dr. Adam Brufsky opens the discussion by introducing the evolving treatment landscape for patients with HR-positive/HER2-negative metastatic breast cancer.
Experts share vital insights on managing HR-positive breast cancer, emphasizing education, patient quality of life, and the evolving landscape of therapies.
Engaging Long-Term HR Positive Metastatic Patients in Shared Decision Making
Clinicians explore essential pre-treatment assessments and monitoring strategies to manage toxicities from new cancer therapies effectively.
Early intervention in cancer treatment aims to enhance patient quality of life and longevity, balancing therapy effectiveness with individual needs.
Experts discuss the evolving landscape of breast cancer treatment, emphasizing the importance of ctDNA testing for personalized therapy decisions.
Experts discuss balancing efficacy and quality of life in SERD therapies, highlighting unique toxicities and the importance of patient education.
Early detection of ESR1 mutations in breast cancer enhances treatment strategies, potentially improving patient outcomes and quality of life.
Clinicians explore the differences between EMERALD and EMBER3 trials, focusing on patient characteristics, treatment efficacy, and future therapy roles.
Oral SERDs emerge as a standard treatment for HR-positive, HER2-negative metastatic breast cancer, especially for patients with ESR1 mutations.
Oral SERDs emerge as a standard treatment for HR-positive, HER2-negative metastatic breast cancer, especially for patients with ESR1 mutations.
Experts discuss the impact of biomarkers and treatment duration on decision-making for CDK4/6 inhibitors in breast cancer adjuvant therapy.
Discover effective strategies for managing toxicities in patients using CDK4/6 inhibitors, ensuring adherence and optimal treatment outcomes.
Clinicians explore barriers to adjuvant CDK4/6-inhibitor therapy, emphasizing education and streamlined communication to improve patient outcomes.
Experts discuss advancements in HR-positive breast cancer treatment, focusing on CDK4/6 inhibitors, SERDs, and early intervention strategies.
Experts discuss advancements in HR-positive breast cancer treatment, focusing on CDK4/6 inhibitors, SERDs, and early intervention strategies.
CDK4/6 Inhibition in HR-Positive Breast Cancer: Evolving Standards in Early and Metastatic Care
Panelists discuss how the field has made exciting strides, with oral selective estrogen receptor degraders (SERDs) likely moving into early-stage disease and the need for alternative antibody-drug conjugate (ADC) payloads beyond topoisomerase I inhibitors to overcome resistance mechanisms.
Panelists discuss how HER2 testing challenges for identifying HER2-low and -ultralow expression require coordination with pathologists and may involve
Panelists discuss how they approach sequencing decisions for patients with hormone receptor–positive, HER2- low/ultralow disease, emphasizing selective use of trastuzumab deruxtecan in first-line chemotherapy settings while considering quality-of-life factors.
Panelists discuss how subgroup analyses from DESTINY-Breast06 show trastuzumab deruxtecan benefits across different mutation groups, with particularly strong responses in patients with BRCA1/2-mutated disease due to the topoisomerase I inhibitor payload.
Panelists discuss how treatment options for HER2-low and HER2-ultralow metastatic breast cancer include trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan, with sequencing becoming a key consideration.
Panelists discuss how to manage toxicities associated with datopotamab deruxtecan, particularly ocular toxicity and stomatitis, using prophylactic measures such as steroid mouthwash and eye drops.
Panelists discuss how datopotamab deruxtecan from the TROPHY-PD-01 trial compares with sacituzumab govitecan, highlighting different toxicity profiles and the challenge of sequencing multiple antibody-drug conjugates (ADCs) with the same TROP2 payload.
Panelists discuss how the TROPiCS-02 trial established sacituzumab govitecan for hormone receptor–positive, HER2-negative metastatic breast cancer and how it influences sequencing decisions with other antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan.
Panelists discuss how they decide when to transition from endocrine-based therapies to antibody-drug conjugates, considering factors such as endocrine sensitivity, disease burden, and pace of progression.
Panelists discuss how to approach decision-making among PI3K/AKT pathway inhibitors (capivasertib, alpelisib, everolimus) based on mutation status, toxicity profiles, and dosing schedules in the second-line setting.
